Chattem’s Dexatrim Looks For Cost-Conscious Consumers Unfriendly To Alli
This article was originally published in The Tan Sheet
Executive Summary
Chattem has not delivered a counter-punch to GlaxoSmithKline's alli, but the firm sees its Dexatrim supplement as "the only one left standing" to compete in the nonprescription weight-loss product categoryYou may also be interested in...
Petition Requests Pre-Market Approval For Supplement Weight-Loss Claims
Chattem Posts Strong Q1 On Selsun Blue Naturals, ACT, Cortisone
Chattem Sales Up 51% Behind Ongoing Push From J&J Acquisitions
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: